IMAGENETIX, INC., (OTCBB: IAGX)

Imagenetix, Inc.
(OTC BB: IAGX)
Investor Kit

$1.25

Imagenetix (“IAGX” or the “Company”) is a novel neutraceutical company based in San Diego, CA. The Company’s main focus is on scientifically validated products which deal with inflammation. The Company uses clinical data, medical validation, and journal presented articles to bolster the pedigree of their products and aid in their distribution. They brand their products and aim to broadly mass market them through multiple national distribution channels. The Company also has direct sales predominantly in international markets on a private label basis. The strategy of the Company is to continue to diversify its branded product base in order to drive further branded products, expand sales to existing distributors, and potentially move into clinically approved products. All of this will be driven by sales of its flagship, trademark and patent protected product Celadrin. We believe that regardless of the immediate challenges IAGX faces, that gaining traction with even one of its existing potential vendors would catapult its valuation. For this reason we are initiating coverage of IAGX with a “Speculative Buy” recommendation and a 12-month price target of $1.25.
Click Here For Full Report

Overview
The company was founded as a bioceutical company that develops products which have pharmacological benefits. As an innovator of proprietary, patented, bioceutical products, Imagenetix focuses on:

• Science driven products and pharmaceutical therapies related to conditions caused by inflammation
• Novel compounds which are patent protected and sold as nutritional supplements
• Imagenetix markets its nutritional products under its own brand, which are based on science and sold primarily in the mass market channel of distribution
• Imagenetix also markets nutritional and OTC pain cream products on a private label basis. Sales of the Company’s private label business is primarily generated internationally
• The Company also has several compounds under drug development for the treatment of inflammatory related diseases

Recent News: Imagenetix Inc.

09/30/09 7:02 AM EDT	RedChip Visibility Initiates Research Coverage On Imagenetix - GlobeNewswire
09/28/09 9:15 AM EDT	Imagenetix, Inc. Announces Shareholders' Meeting - PR Newswire
09/24/09 9:15 AM EDT	Imagenetix, Inc. to Present at the 2009 RedChip New York Equities Conference - PR Newswire
08/26/09 9:15 AM EDT	Letter to Shareholders From Imagenetix, Inc. President/CEO William Spencer - PR Newswire
08/25/09 8:43 AM EDT	RedChip Announces Its 2009 New York Equities Conference At the NASDAQ MarketSite- GlobeNewswire
08/19/09 9:15 AM EDT	Imagenetix, Inc. Expands InflameAway Celadrin(R) in Retail Markets - PR Newswire